Effect of the GLP-1 receptor agonist lixisenatide on counterregulatory responses to hypoglycemia in subjects with insulin-treated type 2 diabetes

Diabetes Care

Volumn 39, Issue 2, 2016, Pages 242-249

  Farngren, Johan ^a   Persson, Margaretha ^a   Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; LIXISENATIDE; METFORMIN; NORADRENALIN; PANCREAS POLYPEPTIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PEPTIDE; ZP10A PEPTIDE;

ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; COUNTERREGULATORY RESPONSE; CROSSOVER PROCEDURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HEMOGLOBIN BLOOD LEVEL; HORMONAL REGULATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERINSULINEMIC HYPOGLYCEMIC CLAMP; HYPOGLYCEMIA; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; TREATMENT DURATION; AGONISTS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED;

BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROCORTISONE; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PEPTIDES;

EID: 84962110250     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1274     Document Type: Article

References (33)

1. Dunning BE, Foley JE, Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005;48: 1700-1713
2. Israelian Z, Szoke E, Woerle J, et al. Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus. Metabolism 2006;55:593-598
3. Ahrén B. Glucagon-Early breakthroughs and recent discoveries. Peptides 2015;67:74-81
4. Christensen M, Bagger JI, Vilsbøll T, Knop FK. The alpha-cell as target for type 2 diabetes therapy. Rev Diabet Stud 2011;8:369-381
5. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-2940
6. Ahrén B. GLP-1 for type 2 diabetes. Exp Cell Res 2011;317:1239-1245
7. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocri-nol Metab 2003;88:3082-3089
8. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002;51:424-429
9. Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013;9:155-163
10. Cryer PE. Minireview: glucagon in the pathogenesis of hypoglycemia and hypergly-cemia in diabetes. Endocrinology 2012;153: 1039-1048
11. Nauck MA, Heimesaat MM, Behle K, et al. Effectsofglucagon-like peptide1on counterregu-latory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239-1246
12. Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397-2403
13. Hompesch M, Jones-Leone A, Carr MC, et al. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus. Diabetes Obes Metab 2015;17:82-90
14. Ahrén B. Insulin plus incretin: a glucose-lowering strategy for type 2-diabetes. World J Diabetes 2014;5:40-51
15. Inzucchi E, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes. 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149
16. Inzucchi E, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-442
17. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154: 103-112
18. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014;384: 2228-2234
19. Charbonnel B, Bertolini M, Tinahones FJ, Domingo MP, Davies M. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complications 2014; 28:880-886
20. Christensen M, Knop FK, Vilsbøll T, Holst JJ. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs 2011;20:549-557
21. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 Get-Goal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35: 1225-1231
22. Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013;36:2543-2550
23. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36:2489-2496
24. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013;36:2497-2503
25. Matsuo T, Miyagawa J, Kusunoki Y. Postab-soptive hyperglucagonemia in patients with type 2 diabetes mellitus analysed with a novel enzyme-linked immunosorbent assay. J Diabetes Investig. 24 August 2015 [Epub ahead of print]. DOI: 10.1111/jdi.12400
26. Ahrén B, Gautier JF, Berria R, Stager W, Aronson R, Bailey CJ. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:861-868
27. Cryer PE. Hypoglycemia-associated auto-nomic failure in diabetes. Handb Clin Neurol 2013;117:295-307
28. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114:115-121
29. Ahrén B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:473-478
30. Taborsky GJ Jr, Mundinger TO. Minire-view: the role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology 2012;153: 1055-1062
31. Schwartz TW, Holst JJ, Fahrenkrug J, et al. Vagal, cholinergic regulation of pancreatic poly-peptide secretion. J Clin Invest 1978;61:781-789
32. Khoo EYH, Wallis J, Tsintzas K, Macdonald IA, Mansell P. Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise. Diabetologia 2010;53:139-143
33. Davis SN, Fowler S, Costa F. Hypoglycemic counterregulatory responses differ between men and women with type 1 diabetes. Diabetes 2000;49:65-72